PURPOSE: Peritoneal recurrence of ovarian cancer is frequent after primary 
surgery and chemotherapy and has poor long-term survival. De novo cytoreductive 
surgery is crucial with the potential to improve prognosis, especially when 
combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
METHODS: The sampled data of 40 consecutive patients were retrospectively 
analyzed. Thirty-one patients were treated with cytoreductive surgery combined 
with hyperthermic intraperitoneal chemotherapy.
RESULTS: No patient was lost in the perioperative period, and the combined 
procedure was performed with acceptable morbidity. Colon-preserving 
cytoreductive surgery was associated with reduced morbidity.
CONCLUSIONS: Patients suffering from peritoneal recurrence of ovarian cancer 
should be considered for radical reoperation with HIPEC in a center with 
expertise in multimodal therapeutic options. Organ-preserving cytoreductive 
surgery allows complete cytoreduction with the goal of decreasing morbidity.